Haleon misses its own revenue target for the year as a mild winter and a cautious American consumer drag organic growth to 3%

The consumer health group behind Sensodyne and Panadol fell short of its 4-6% medium-term benchmark, but delivered double-digit profit growth and strong cash generation that management says keeps the longer-term case intact

Haleon PLC (LSE:HLN, NYSE:HLN) ended 2025 below its own expectations on the measure that matters most to investors.

Organic revenue growth of 3% for the full year came in a full percentage point below the floor of the 4-6% medium-term range the company set for itself, the result of two headwinds that converged in the second half and proved harder to offset than the business had anticipated.

The first was the American consumer. North America, which accounts for 35% of Haleon's revenues, contracted 0.4% organically across the year as shoppers pulled back on spending amid persistent inflation and anxiety about the labour market.

The weakness was concentrated in more discretionary categories, with Smokers' Health declining by double-digit and the multivitamin segment under pressure from competitive promotions. Even in a resilient category like oral health, the US consumer added drag.

The second was the weather. A notably weak cold and flu season, particularly in North America and Central and Eastern Europe in the fourth quarter, cost Haleon an estimated 150 basis points of organic growth in that period alone and 40 basis points across the full year.

Robitussin declined double-digit in the fourth quarter with lower levels of cough incidence. The company was candid that a normal season would have produced a meaningfully different result.

The profit performance that softens the blow

What prevents the revenue miss from being the whole story is the distance Haleon has opened up between its top and bottom lines. Adjusted operating profit grew 10.5% organically to £2.526 billion, with margin expanding 160 basis points to 22.9% on an organic basis.

Free cash flow reached £1.913 billion, up £194 million on a like-for-like basis once the prior year's ChapStick disposal proceeds are removed. Net debt fell to 2.6 times adjusted EBITDA, close to the company's 2.5 times target.

That outperformance on profit reflects a supply chain productivity programme targeting £800 million in gross savings over five years, which is already delivering. SKU counts are down 26%, packaging specifications have been cut by 22%, and the consolidation of Haleon's artwork network into a single centre in Poland has halved costs in that function. The programme is expected to contribute 50 to 80 basis points of gross margin expansion per year at constant currency over the medium term.

Where the business held up and where it did not

Oral health, Haleon's largest category at 32% of revenues, grew 7.9% organically, driven by Sensodyne's clinical product range and a successful expansion of Parodontax into China.

Asia-Pacific delivered 5.2% organic growth, with India posting double-digit gains and China growing mid-single digit. EMEA and Latin America grew 4.7%, with broad-based strength across the Middle East, Africa and parts of Europe.

Respiratory health was the clearest casualty of the cold and flu miss, contracting 1.9% organically. Pain relief and digestive health each managed modest positive growth. Vitamins, minerals and supplements grew 1.9%, with Centrum recovering in North America in the second half after a weak start.

What 2026 is should look like

Haleon is guiding for organic revenue growth of 3-5% in 2026 and high single-digit adjusted operating profit growth at constant currency.

A new operating model announced in January, built around six regional units and a newly created Chief Growth Officer role, is expected to generate annualised gross savings of £175 million to £200 million over two years, though the restructuring costs are expected to roughly match those savings in the near term.

The company is returning £500 million to shareholders via buybacks in 2026, continuing a programme that distributed £1.1 billion in 2025.

The total dividend for the year is 7.1p per share, up 7.6%, with a final dividend of 4.9p subject to shareholder approval. Chief executive Brian McNamara said he remains confident in the medium-term guidance, pointing to brand resilience and 60% of the business gaining or maintaining market share during the year.

The guidance range for 2026 sits entirely within the medium-term target. Whether that is reassurance or a low bar will depend on whether the cold and flu season, and the American consumer, cooperate.